Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00208546 | Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer | PHASE3 | COMPLETED | 750 | — | — | Jun 1, 2005 | Dec 1, 2009 | Feb 2, 2012 | 1 | Netherlands |
| Arm | Type | Description |
|---|---|---|
| 1Capecitabine + bevacizumab + oxaliplatin + cetuximab | EXPERIMENTAL | - |
| 21Capecitabine + bevacizumab + oxaliplatin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 21Capecitabine + bevacizumab + oxaliplatin | DRUG | 3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1. |
| 1Capecitabine + oxaliplatin + bevacizumab + cetuximab | DRUG | 3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2). |
Inclusion Criteria: Histology and Staging Disease * Histologically proven advanced colorectal cancer (CRC); not amenable to curative surgery * Of Note: In case of a single metastasis, histological or cytological proof of colorectal carcinoma should be obtained prior to randomisation. * Unidimensio...